Valuation: Atossa Therapeutics, Inc.

Market Cap 19.89M 17.23M 16.06M 14.77M 27.89M 1.89B 28.2M 189M 74.07M 946M 74.71M 73.06M 3.13B P/E 2026 *
-0.53x
P/E 2027 * -0.67x
Enterprise Value 19.89M 17.23M 16.06M 14.77M 27.89M 1.89B 28.2M 189M 74.07M 946M 74.71M 73.06M 3.13B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+2.92%
1 week+2.92%
Current month+14.86%
1 month+4.28%
3 months-57.39%
6 months-55.39%
Current year-73.14%
1 week 2.05
Extreme 2.05
2.39
1 month 2.05
Extreme 2.05
2.6
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
64.65
10 years 1.7
Extreme 1.7
756
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
20/1/26 Free

Chief Executive Officer

1,281,674 0.9922%
20/1/26
Ensisheim Partners LLC
OtherCompany 0 0%
14/10/25 Free

Chief Financial Officer

578,000 0.4595%
Change 5-day change 1-year change 3-year change Capi.($)
+3.46%+2.92%-80.31%-84.76% 19.89M
+0.90%+0.21%-0.74%+13.87% 48B
+1.98%+8.90%+413.21%+564.71% 41.13B
+3.44%-4.64%+28.35%+7.65% 37.56B
+1.40%+0.07%+6.58%+74.62% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
-0.16%-3.17% - - 16.12B
+2.20%+0.52%+34.76%+125.80% 16.05B
+1.25%+1.69%+4.72%+18.26% 13.76B
+4.25%-8.31%-1.57%-35.06% 12.1B
Average +1.98%-2.37%+46.65%+81.10% 25.05B
Weighted average by Cap. +1.77%-1.29%+82.37%+128.16%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.39M -30.19M -27.77M -52.42M -3.56B -53M -355M -139M -1.78B -140M -137M -5.89B -39.31M -34.05M -31.74M -29.19M -55.11M -3.74B -55.73M -373M -146M -1.87B -148M -144M -6.19B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
06/08/26 US$2.390 +3.46% 35,259
04/08/26 US$2.310 +6.45% 54,974
03/08/26 US$2.170 +4.83% 24,344
31/07/26 US$2.070 -5.48% 79,045
30/07/26 US$2.190 -5.19% 32,533
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.310USD
Average target price
22.00USD
Spread / Average Target
+852.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock